人卵巢癌細胞PEO4

細胞名稱

人卵巢癌細胞PEO4

貨物編碼

BFN60808598

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研      2類

培養體系

DMEM高糖培養基+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡介

人卵巢癌細胞PEO4取自女性供體腹水。該細胞源于ECACC

注釋

Part of: OCCP ovarian cancer cell line panel.

Doubling time: 59 hours (PubMed=3583449); 36 hours (PubMed=3167863).

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep RNAseq analysis.

Omics: Transcriptome analysis.

基因突變

Hemizygous for BRCA2 p.Tyr1655Tyr (5193C>T); de novo mutation that cancels the 5193C>G mutation in the patient (PubMed=19654294).

TP53 p.Gly244Asp (c.731G>A) (PubMed=25230021; PubMed=28273451; DepMap).

HLA信息

Class I

HLA-A        A*03:01,03:01

HLA-B        B*07:02,07:02

HLA-C        C*07:02,07:02

Class II

HLA-DR        DRB1*11:01,04:05

STR信息

Amelogenin        X

CSF1PO        10,12

D2S1338        20,21

D3S1358        16

D5S818        11,12

D7S820        10

D8S1179        13,14

D13S317        10

D16S539        9

D18S51        16,17

D19S433        13,15

D21S11        30,32.2

FGA        20

Penta D        9,14

Penta E        11,12

TH01        9.3

TPOX        9,11

vWA        15,16

參考文獻

PubMed=25230021; DOI=10.1371/journal.pone.0103988

Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

PLoS ONE 9:E103988-E103988(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:E954893-E954893(2014)

PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028

Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F., Noonan A.M., Annunziata C.M.

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Gynecol. Oncol. 142:332-340(2016)

PubMed=27561551; DOI=10.1038/ncomms12645

Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.

Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.

Nat. Commun. 7:12645-12645(2016)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028

Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P., Novak M., Doodnauth S.A., Saiz F.S., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R., Ailles L., Mes-Massons A.-M., Rottapel R.

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Cell Rep. 18:2343-2358(2017)